HIV-1 infection in injection drug users

Infectious Disease Clinics of North America

Volumn 16, Issue 3, 2002, Pages 745-770

  Cohn, Jonathan Allen ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

DISINFECTION; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; NEEDLE; OPPORTUNISTIC INFECTION; PREVALENCE; REVIEW; SEXUALLY TRANSMITTED DISEASE; SYRINGE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; FEMALE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; PREVALENCE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULOSIS; UNITED STATES;

EID: 0036739862     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(02)00012-0     Document Type: Review

References (123)

1. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994;331(7):450-9.
2. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. 2000; 12(2):14-5, 18, 35.
3. Centers for Disease Control and Prevention. HIV prevention strategic plan through 2005; January 2001. http://www.cdc.gov/hiv/pubs/prev-strat-plan.pdf. Accessed August 1, 2002.
4. Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health 2000;90(3):352-9.
5. Des Jarlais DC, Hagan H, Friedman S. HIV among injecting drug users: epidemiology and emerging public health perspectives. In: Merigan TC, Bartlett JG, Bolognesi D, editors. Textbook of AIDS medicine. 2nd edition. Baltimore (MD): Williams and Wilkins; 1999. p. 179-90.
6. UNAIDS. AIDS epidemic update December 2001. Geneva, Switzerland: Joint United Nations Program on AIDS/ World Health Organization. http://www.unaids.org/ worldaidsday/2001/Epiupdate2001/EPIupdate2001_en.doc. Accessed August 1, 2002.
7. Mezzelani P, Quaglio GL, Venturini L, et al. A multicentre study on the causes of death among Italian injecting drug users. AIDS has overtaken overdose as the principal cause of death. AIDS Care 1998;10(1):61-7.
8. Abdala N, Stephens PC, Griffith BP, et al. Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(1):73-80.
9. Shapshak P, Fujimura RK, Page JB, et al. HIV-1 RNA load in needles/syringes from shooting galleries in Miami: a preliminary laboratory report. Drug Alcohol Depend 2000;58(1-2):153-7.
10. Nelson KE, Vlahov D, Cohn S, et al. Human immunodeficiency virus infection in diabetic intravenous drug users. JAMA 1991;266(16):2259-61.
11. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med 2001; 161(10):1281-8.
12. Kral AH, Bluthenthal RN, Lorvick J, et al. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001;357(9266):1397-401.
13. Janssen RS, Holtgrave DR, Valdiserri RO, et al. The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health 2001; 91(7):1019-24.
14. Celentano DD, Munoz A, Cohn S, et al. Dynamics of behavioral risk factors for HIV/ AIDS: a 6-year prospective study of injection drug users. Drug Alcohol Depend 2001; 61(3):315-22.
15. Des Jarlais DC, Friedmann P, Hagan H, et al. The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use. Am J Public Health 1996;86(12):1780-5.
16. Dolezal C, Meyer-Bahlburg HF, Liu X, et al. Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Am J Drug Alcohol Abuse 1999;25(2):281-303.
17. Centers for Disease Control and Prevention. Recommendations for HIV testing services for inpatients and outpatients in acute care hospital settings. MMWR Morb Mortal Wkly Rpt 1993;42(RR-2):1-6.
18. Janssen RS, St Louis ME, Satten GA, et al. HIV infection among patients in U.S. acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance Group. N Engl J Med 1992;327(7):445-52.
19. Kelen D, Hexter DA, Hansen KN, et al. Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program. Ann Emerg Med 1996;27(6):687-92.
20. Stetler HC, Granade RC, Nunez CA, et al. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. AIDS 1997;11:369-75.
21. Gibson DR, McCusker J, Chesney M. Effectiveness of psychosocial interventions in preventing HIV risk behavior in injecting drug users. AIDS 1998;12(8):919-29.
22. Des Jarlais DC, Friedman SR. Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep 1998;113(Suppl 1):182-8.
23. Comacho LM, Bartholomew NG, Joe GW, et al. Maintenance of HIV risk reduction among injection opioid users: a 12 month post treatment follow-up. Drug Alcohol Depend 1997;47(1):11-8.
24. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000;90(7):1100-11.
25. Carlson RG, Wang J, Siegal HA, et al. A preliminary evaluation of a modified needle-cleaning intervention using bleach among injection drug users. AIDS Educ Prev 1998; 10(6):523-32.
26. Gleghorn AA, Doherty MC, Vlahov D, et al. Inadequate bleach contact times during syringe cleaning among injection drug users. J Acquir Immune Defic Syndr 1994;7(7):767-72.
27. McCoy CB, Rivers JE, McCoy HV, et al. Compliance to bleach disinfection protocols among injecting drug users in Miami. J Acquir Immune Defic Syndr 1994;7(7):773-6.
28. Bluthenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14(5):605-11.
29. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996;348(9033):987-91.
30. Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). J Acquir Immune Defic Syndr 2000;25(1):63-70.
31. Strathdee SA, Celentano DD, Shah N, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health 1999;76(4):448-60.
32. Brooner R, Kidorf M, King V, et al. Drug abuse treatment success among needle exchange participants. Public Health Rep 1998;113(Suppl 1):129-39.
33. Schechter MT, Strathdee SA, Cornelisse PG, et al. Do needle exchange programs increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS 1999;13(6):F45-51.
34. Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol 1997;146(12):994-1002.
35. Gleghorn AA, Gee G, Vlahov D. Pharmacists' attitudes about pharmacy sale of needles/ syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S89-93.
36. Keyl PM, Gruskin L, Casano K, et al. Community support for needle exchange programs and pharmacy sale of syringes: a household survey in Baltimore, Maryland. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1998;18(Suppl 1): S82-8.
37. Burris S, Lurie P, Abrahamson D, Rich JD. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. Ann Intern Med 2000;133(3):218-26.
38. Rich JD, Macalino GE, McKenzie M, et al. Syringe prescription to prevent HIV infection in Rhode Island: a case study. Am J Public Health 2001;91(5):699-700.
39. Holtgrave DR, Pinkerton SD, Jones TS, et al. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S133-8.
40. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998;83(1-2):77-87.
41. Yu XF, Wang Z, Vlahov D, et al. Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users. J Infect Dis 1998;178(2):388-96.
42. Spijkerman IJB, Koot M, Prins M, et al. Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS 1995;9:1085-92.
43. Alexander CS, Dong W, Schechter MT, et al. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. AIDS 1999;13(8):981-5.
44. Carneiro M, Yu XF, Lyles C, et al. The effect of drug-injection behavior on genetic evolution of HIV-1. J Infect Dis 1999;180(4):1025-32.
45. Schinkel J, Langendam MW, Coutinho RA, et al. No evidence for an effect of the CCR5 delta32/+ and CCR2b 641/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis 1999;179(4):825-31.
46. Alvarez V, Lopez-Larrea C, Coto E. Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co- receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. Hum Genet 1998;102(4):483-6.
47. Beretta A, Weiss SH, Rappocciolo G, et al. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis 1996;173(2):472-6.
48. Routy JP, Vanhems P, Rouleau D, et al. Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use. The Investigators of the Quebec Primary HIV Infection Study. J Acquir Immune Defic Syndr 2000;24(5): 425-32.
49. Hendriks JC, Satten GA, van Ameijden EJ, et al. The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis. AIDS 1998;12(12):1537-44.
50. Pezzotti P, Galai N, Vlahov D, et al. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(3):275-82.
51. Prins M, Hernandez Aguado IH, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997;11(14):1747-56.
52. Lyles CM, Dorrucci M, Vlahov D, et al. Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis 1999;180(4):1018-24.
53. Lyles CM, Graham NM, Astemborski J, et al. Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Eur J Epidemiol 1999;15(2):99-108.
54. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998;279(1):35-40.
55. Lyles CM, Margolick JB, Astemborski J, et al. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users. AIDS 1997;11(10):1255-62.
56. Krol A, Flynn C, Vlahov D, et al. New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Drug Alcohol Depend 1999;54(2):145-54.
57. Mientjes GHC, Miedema F, van Ameigden EJC, et al. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 1991;186: 35-41.
58. Jones JL, Hanson DL, Dworkin MS, et al. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. J Infect Dis 1998;178(1):114-20.
59. Martin V, Cayla JA, Bolea A, et al. Mycobacterium tuberculosis and human immunodeficiency virus co-infection in intravenous drug users on admission to prison. Int J Tuberc Lung Dis 2000;4(1):41-6.
60. Salomon N, Perlman DC, Friedmann P, et al. Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program. Int J Tuberc Lung Dis 2000;4(1):47-54.
61. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with HIV. www.hivatis.org/trtgdlns.html. Accessed August 1, 2002.
62. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997;337(5):315-20.
63. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among persons infected with HIV: principals of therapy and revised recommendations. MMWR Morb Mortal Wkly Rpt 1998;47(RR-20):24-35.
64. Bodsworth NJ, Cooper DA. Donovan B The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163(5):1138-40.
65. Sinicco A, Raiteri R, Sciandra M, et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis 1997;29(2):111-5.
66. Smith RM, Wu GY. Molecular virology of hepatitis B and C: clinical implications. In: Koff RS, Wu GY, editors. Chronic viral hepatitis: diagnosis and therapeutics. Totowa (NJ): Humana Press; 2001. p. 2.
67. Angtuaco TL, Jensen DM. HBV and HCV co-infection. In: Koff RS, Wu GY, editors. Chronic viral hepatitis: diagnosis and therapeutics. Totowa (NJ): Humana Press; 2001. p. 109-22.
68. Berger A, Doerr HW, Rabenau HF, et al. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000;43(2):71-6.
69. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341(1):22-6.
70. Grob P, Jilg W, Bornhak H, et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000;62(4):450-5.
71. di Martino V, Lunel F, Cadranel JF, et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat 1996;3(5):253-60.
72. Zylberberg H, Jiang J, Pialoux G, et al. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996; 20(11):968-71.
73. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
74. Lai CL, Chien RN, Leung NWY, et al. One-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
75. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33(6):1527-32.
76. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7.
77. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46(4):562-8.
78. Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180(3): 607-13.
79. Hoff J, Bani-Sadr F, Gassin M, et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001;32(6):963-9.
80. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30(5):1302-6.
81. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28(5):1032-5.
82. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32(1):144-8.
83. Kreek MJ, Des Jarlais DC, Trepo CL, et al. Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. J Infect Dis 1990;162(2): 538-41.
84. Buti M, Jardi R, Allende H, et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol 1996;49(1):66-9.
85. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999;30(2):579-81.
86. Puoti M, Rossi S, Forleo MA, et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol 1998;29(1):45-52.
87. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998; 28(6):945-50.
88. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001;183(7):1112-5.
89. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIVinfected patients with chronic hepatitis C. Am J Gastroenterol 2001;96(1):179-83.
90. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356(9244):1800-5.
91. Staples Jr CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999;29(1):150-4.
92. Sulkowsi MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with anti-retroviral therapy in adults infected with the human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
93. Sustiva (efavirenz) capsules prescribing information. Princeton (NJ): BMS Virology, Bristol-Meyers Squibb Company; April, 2002.
94. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14(18):2895-902.
95. Landau A, Batisse D, Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000;14(15):2409-10.
96. Nasti G, Di Gennaro G, Tavio M, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 2001; 15(14):1783-7.
97. Poles MA, Dietereich DT. Hepatitis C and HIV co-infection. In: Koff RS, Wu GY, editors. Chronic viral hepatitis: diagnosis and therapeutics. Totowa (NJ): Humana Press; 2001. p. 95-108.
98. Sauleda S, Juarez A, Esteban JI, et al. J. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;34(5):1035-40.
99. Tillman HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001;345(10):715-24.
100. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001;345(10):707-14.
101. Goedert JJ, Fung MW, Felton S, et al. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001;15(10): 1295-302.
102. Safaeian M, Wilson LE, Taylor E, et al. HTLV-II and bacterial infections among injection drug users. J Acquir Immune Defic Syndr 2000;24(5):483-7.
103. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995;333(13):845-51.
104. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285(11):1466-74.
105. Swindells S, Zheng J, Gendelman HE. HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions. AIDS patient care and STDs 1999;13(3):153-63.
106. Bell JE, Brettle RP, Chiswick A, et al. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 1998;121(Pt 11):2043-52.
107. Bouwman FH, Skolasky RL, Hes D, et al. Variable progression of HIV-associated dementia. Neurology 1998;50(6):1814-20.
108. Egan VG, Crawford JR, Brettle RP, et al. The Edinburgh cohort of HIV-positive drug users: current intellectual function is impaired, but not due to early AIDS dementia complex. AIDS 1990;4(7):651-6.
109. Egan V, Brettle RP, Goodwin GM. The Edinburgh cohort of HIV-positive drug users: pattern of cognitive impairment in relation to progression of disease. Br J Psychiatry 1992;161:522-31.
110. Goodwin GM, Pretsell DO, Chiswick A, et al. The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia. AIDS 1996;10(4):431-40.
111. Selnes OA, Galai N, McArthur JC, et al. HIV infection and cognition in intravenous drug users: long- term follow-up. Neurology 1997;48(1):223-30.
112. Starace F, Baldassarre C, Biancolilli V, et al. Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand 1998;97(2):132-8.
113. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001;33(6):847-56.
114. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. The living document. Department of Health and Human Services and the Henry J. Kaiser Foundation, February 4, 2002. www.hivatis.org/trtgdlns.html. Accessed August 1, 2002.
115. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133(1):21-30.
116. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001;33(6):865-72.
117. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999;22(4):369-78.
118. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 2001;15(3):423-4.
119. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15(9):1115-23.
120. Antela A. Access to antiretroviral therapy in HIV-infected injection drug users. AIDS 2001;15(13):1727-8.
121. Moreno A, Perez-Ewlias MJ, Casado JL, et al. Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naïve HIV-infected injection drug users on methadone maintenance programs. AIDS 2001;15(8):1068-70.
122. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15(13):1707-15.
123. Knowlton AR, Hoover DR, Chung SE, et al. Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug Alcohol Depend 2001;64(1):55-62.